VVUS - VIVUS, Inc.
| Previous Close | 2.7800 |
| Open | 2.7700 |
| Bid | 2.72 x 900 |
| Ask | 2.91 x 900 |
| Day's Range | 2.6700 - 2.8100 |
| 52 Week Range | 2.5200 - 9.9000 |
| Volume | 57,931 |
| Avg. Volume | 99,209 |
| Market Cap | 29.87M |
| Beta (3Y Monthly) | 1.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.02 |
| Earnings Date | Mar 11, 2019 - Mar 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- Zacks•3 days ago
5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
- Benzinga•4 days ago
The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...
- Zacks•16 days ago
Vivus (VVUS) Down 17% Since Last Earnings Report: Can It Rebound?
Vivus (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire•last month
New Research Coverage Highlights CommVault, Dawson Geophysical, RF Industries, Hennessy Advisors, VIVUS, and Semiconductor Manufacturing International — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•last month
Edited Transcript of VVUS earnings conference call or presentation 1-Nov-18 8:30pm GMT
Q3 2018 Vivus Inc Earnings Call
- Zacks•last month
VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y
VIVUS (VVUS) reports narrower-than-expected loss in the third quarter. Sales increase year over year.
- Associated Press•last month
Vivus: 3Q Earnings Snapshot
The Campbell, California-based company said it had a loss of 87 cents per share. The biopharmaceutical company posted revenue of $18.1 million in the period. In the final minutes of trading on Thursday, ...
- GlobeNewswire•last month
VIVUS Reports Third Quarter 2018 Financial Results
Company to host conference call today at 4:30pm ET CAMPBELL, Calif., Nov. 01, 2018 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company.
- GlobeNewswire•2 months ago
VIVUS Adds Two New Members to the Board of Directors
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, today announced that Karen Ferrell and Edward A. Kangas have been appointed to VIVUS’ board of directors. “We welcome Karen and Ed, both of whom bring significant board experience including corporate governance, healthcare, managed care, finance and pharmaceuticals,” said John Amos, Chief Executive Officer at VIVUS.
- GlobeNewswire•2 months ago
VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Thursday, November 1, 2018
CAMPBELL, Calif., Oct. 26, 2018 -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the third quarter of.
- GlobeNewswire•2 months ago
VIVUS to Present at the BIO Investor Forum on October 17, 2018
CAMPBELL, Calif., Oct. 10, 2018 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of.
- GlobeNewswire•3 months ago
VIVUS Regains Compliance with Nasdaq Listing Requirements
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical needs in human health, announced today that it has regained full compliance with Nasdaq listing requirements. In a letter dated September 25, 2018, Nasdaq informed the Company that it has achieved compliance with the minimum bid price rule and is in compliance with other applicable requirements required for continued listing on The Nasdaq Capital Market. “When we assembled the new management team in April, combining three new officers with the existing VIVUS team, we articulated a set of key priorities.
- GlobeNewswire•3 months ago
VIVUS to Present at the Fourth Annual Robins Equity Research Round-Up
CAMPBELL, Calif., Sept. 24, 2018-- VIVUS, Inc.,, a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical needs in human health, announced today ...
- GlobeNewswire•3 months ago
VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundation’s CF Climb
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, announced today that it is supporting the Dallas-Fort Worth chapter of the Cystic Fibrosis Foundation (CFF) in its CF Climb fundraising event. This sponsorship demonstrates VIVUS’ support of the cystic fibrosis (CF) patient community as the Company launches PANCREAZE® (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI), a common complication of CF.
- ACCESSWIRE•3 months ago
New Growth Opportunities Jump for 3 Biotech Stocks in 2018
CORAL GABLES, FL / ACCESSWIRE / September 11, 2018 / Biotech stocks continue to present key drivers of returns for many investors. Public equities have delivered strong returns underpinned by large-scale of monetary policy support. It is particularly noteworthy that the California Public Employees' Retirement System is considering the creation of a direct investment program, which would include investment in companies within sectors like healthcare and biotechnology.
- Zacks•3 months ago
Why Is Vivus (VVUS) Down 6.4% Since Last Earnings Report?
Vivus (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•4 months ago
VIVUS' (VVUS) Qsymia Falters in a Highly Competitive Market
VIVUS' (VVUS) Qsymia sales lackluster due to slow uptake of the drug and a competitive market.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of VVUS earnings conference call or presentation 7-Aug-18 8:30pm GMT
Q2 2018 Vivus Inc Earnings Call
Market Realist•4 months agoA Look at Novo Nordisk’s Human Insulin and Obesity Business
In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.
- Zacks•4 months ago
VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y
VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.
- Associated Press•4 months ago
Vivus: 2Q Earnings Snapshot
The Campbell, California-based company said it had a loss of 12 cents per share. The biopharmaceutical company posted revenue of $15 million in the period. In the final minutes of trading on Tuesday, the ...
